Post-preeclampsia Renal Project: Study of Nephroprotection in Women Having Suffered Preeclampsia (RPPEC)
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Benazepril (ATC N° C09AA07) in the Treatment of Persistent Renal Dysfunction in Pre-eclamptic Women
Studieöversikt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljerad beskrivning
Several epidemiological studies suggest that the risk of death from cardiovascular causes among women with preeclampsia may be increased, and that preeclampsia contrary to what has been long thought, is not cured with delivery. Preeclampsia has long been considered a 2-stage disease, stage one corresponding to an impaired placental perfusion resulting from abnormal spiral artery remodeling, and stage two corresponding to the maternal manifestations of disease, characterized by hypertension and proteinuria. However, preeclampsia might include an additional, 3rd stage, that of the post-partum period (Gammill & Roberts, 2007) This phase deserves to be investigated. In particular, it is crucial to determine whether the changes that occur in renal hemodynamics during preeclampsia are reversible after more than 6 weeks, and whether PEC women are salt-sensitive after delivery.
The link between chronic kidney disease and cardiovascular mortality is well established. An independent, graded association exists between a reduced GFR and the risk of death, cardiovascular events, and hospitalization (Go et al, 2004). Besides, salt-sensitivity is associated with an increased cardiovascular and renal risk (Franco & Oparil, 2006). The Renal Post PEC study aims at establishing if the renal dysfunctions that occur in PEC women can be reversed by the administration of inhibitors of the renin-angiotensin system that are known to improve cardiovascular and renal risk profiles in hypertensive patients. By virtue of their potent renal vasodilatory properties and favourable remodelling of the GBM, ACE inhibitors may improve salt-sensitivity, endothelial function, renal plasma flow and GFR, and general renal prognosis in women who experienced from preeclampsia.
Studietyp
Studietyp
Inskrivning (Faktisk)
Inskrivning
Fas
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
-
Geneva, Schweiz
- Geneva University Hospitals
-
Lausanne, Schweiz
- Centre Hospitalier Universitaire Vaudois
-
-
Deltagandekriterier
Urvalskriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Pre-selection Criteria:
- Normotensive women with no proteinuria before the 20th week of gestation AND
- Women with hypertension (BP ≥140/90 mm Hg) and proteinuria (≥ 0.3 g /24h or 2++ dipstick) after the 20th week of gestation
Inclusion Criteria:
- Clearance of creatinine ≤ 80 ml/min (Gault et Cockcroft)
- Serum creatinine ≥ 80 µmol/L
- Microalbuminuria comprised between 30 and 300 mg/d and/or a urinary spot with microalbuminuria/creatinine ratio ≥ 3.5 and/or macroalbuminuria (24h urinary albumin excretion ≥ 0.500 mg)
- BP ≥ 140/90 mm Hg OR ongoing antihypertensive treatment
- CRP ≥ 4 mg/dL
Exclusion Criteria:
- Those unlikely to co-operate in the study
- Those who refuse to use appropriate contraceptive measures during the treatment period (intrauterine device, oral contraceptives, condom, diaphragm)
- Those with a history of pre-term delivery
- Those with known history of severe allergic reaction
- Those who consume drugs
- Aged < 18 years old
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Antal vapen
Vapen och interventioner
Deltagargrupp / ArmDeltagargrupp / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Placebo-jämförare: Kontrollarm
|
Tablets; oral administration; once a day for 6 months.
After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks.
At the end of this washout period, a new renal evaluation is done.
At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
|
|
Experimentell: Benazepril
|
Tablets (10 or 20 mg); oral administration; once a day for 6 months.
After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks.
At the end of this washout period, a new renal evaluation is done.
At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
microalbuminuria excretion rate (spot or 24h)
Tidsram: Baseline; 1 week + 24 weeks after treatment start
|
Baseline; 1 week + 24 weeks after treatment start
|
|
eGFR
Tidsram: Baseline; 1 week + 24 weeks after treatment start
|
Baseline; 1 week + 24 weeks after treatment start
|
Sekundära resultatmått
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Filtration fraction %
Tidsram: Baseline; 1 week + 24 weeks after treatment start
|
Baseline; 1 week + 24 weeks after treatment start
|
|
|
24h Ambulatory Blood Pressure
Tidsram: Baseline; 1 week and 24 weeks after treatment start
|
Mean; diurnal; nocturnal
|
Baseline; 1 week and 24 weeks after treatment start
|
|
Effective Renal Plasma Flow
Tidsram: Baseline; 1 week and 48 weeks after treatment start
|
Baseline; 1 week and 48 weeks after treatment start
|
|
|
Adverse Events
Tidsram: From signature of informed consent until last follow-up visit (36 months after treatment start)
|
From signature of informed consent until last follow-up visit (36 months after treatment start)
|
Samarbetspartners och utredare
Sponsor
Sponsor
Utredare
Utredare
- Huvudutredare: Antoinette Pechère, University Hospital, Geneva
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Studiestart
Primärt slutförande (Faktisk)
Primärt slutförande
Avslutad studie (Faktisk)
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Första postat
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste uppdatering publicerad
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
Andra studie-ID-nummer
- 09-136
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .